Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.…
LGVN Has Multiple Options
Longeveron (NASDAQ: LGVN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 38 employees.
The shares were at 1.660 USD on 20 November 2026, down 77.5% over 52 weeks. Its 52-week range is 1.317 USD to 12.30 USD: the price is 86.5% below the high and 26.0% above the low.
Its market capitalisation is 5.60M USD.
Longeveron reports return on equity of -400.1% and revenue down 9.2% year over year.
It holds more cash than debt, a net cash position of 9.50M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 March 2027.